Cost Effectiveness of a Lidocaine 5% Medicated Plaster Compared with Pregabalin for the Treatment of Postherpetic Neuralgia in the UK

Ritchie, Mark E.; Liedgens, Hiltrud; Nuijten, Mark

doi:10.2165/11533310-000000000-00000

Cited by 13 publications

(20 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The search identified 797 studies, 20 of which met the inclusion criteria. Of the 20 included studies, 14 presented original model structures 4,5,[16][17][18][19][20][21][22][23][24]27,29,30 , and six used existing model structures populated with data and assumptions that differed from those in the original study 3,25,26,[31][32][33] . Herein, where data and scope are compared, we refer to all 20 included studies, but where model type and structural elements are compared, we compare across the 14 original model structures only.…”

Section: Figure 1 Presents a Preferred Reporting Items For Systematicmentioning

confidence: 99%

“…Results in Table 1 suggest that the volume of cost-effectiveness studies in neuropathic pain is increasing; over 50% of the 20 inclusions (11 studies) were published after January 2010 [3][4][5]17,19,20,25,29,[31][32][33] . This may reflect an emergence of new treatments for neuropathic pain, and an increasing need across jurisdictions to demonstrate cost-effectiveness in order to receive reimbursement for these types of therapies.…”

Section: Figure 1 Presents a Preferred Reporting Items For Systematicmentioning

confidence: 99%

“…The majority of studies identified were European [3][4][5]16,18,[24][25][26]29,[31][32][33] . Pregabalin is the most commonly appraised analgesic across these studies, assessed in all except two European studies 18,24 .…”

Section: Figure 1 Presents a Preferred Reporting Items For Systematicmentioning

confidence: 99%

“…Titration may be important in influencing health and cost outcomes, yet outcomes associated with titration were considered in only three included models 17,24,25 . In studies where titration was not considered, justifications for its omission were generally lacking 18,19,22,29 .…”

Section: Pharmaceutical Therapies In Neuropathic Painmentioning

confidence: 99%

“…These complexities include: patient and treatment heterogeneity; challenges in understanding how treatments affect health outcomes, in particular HRQoL; and understanding the HRQoL and cost implications of multiple, consecutive lines of often ineffective treatment. In 2013, the National Institute for Health and Care Excellence (NICE) in England and Wales reviewed previous economic analyses in neuropathic pain to inform guidance on pharmacological management of neuropathic pain 5 , and were critical of 'potentially serious limitations' in each of the 13 studies identified 4,[16][17][18][19][20][21][22][23][24][25][26][27] . However, the NICE reviewers were not specific in their criticism 5 .…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

A systematic review of cost-effectiveness modeling of pharmaceutical therapies in neuropathic pain: variation in practice, key challenges, and recommendations for the future

Critchlow

Hirst

Akehurst

et al. 2016

Journal of Medical Economics

View full text Add to dashboard Cite

Objectives: Complexities in the neuropathic-pain care pathway make the condition difficult to manage and difficult to capture in cost-effectiveness models. The aim of this study is to understand, through a systematic review of previous cost-effectiveness studies, some of the key strengths and limitations in data and modeling practices in neuropathic pain. Thus, the aim is to guide future research and practice to improve resource allocation decisions and encourage continued investment to find novel and effective treatments for patients with neuropathic pain. Methods: The search strategy was designed to identify peer-reviewed cost-effectiveness evaluations of non-surgical, pharmaceutical therapies for neuropathic pain published since January 2000, accessing five key databases. All identified publications were reviewed and screened according to pre-defined eligibility criteria. Data extraction was designed to reflect key data challenges and approaches to modeling in neuropathic pain and based on published guidelines. Results: The search strategy identified 20 cost-effectiveness analyses meeting the inclusion criteria, of which 14 had original model structures. Cost-effectiveness modeling in neuropathic pain is established and increasing across multiple jurisdictions; however, amongst these studies, there is substantial variation in modeling approach, and there are common limitations. Capturing the effect of treatments upon health outcomes, particularly health-related quality-of-life, is challenging, and the health effects of multiple lines of ineffective treatment, common for patients with neuropathic pain, have not been consistently or robustly modeled. Conclusions: To improve future economic modeling in neuropathic pain, further research is suggested into the effect of multiple lines of treatment and treatment failure upon patient outcomes and subsequent treatment effectiveness; the impact of treatment-emergent adverse events upon patient outcomes; and consistent and appropriate pain measures to inform models. The authors further encourage transparent reporting of inputs used to inform cost-effectiveness models, with robust, comprehensive and clear uncertainty analysis and, where feasible, open-source modeling is encouraged. ARTICLE HISTORY

show abstract

Section: Figure 1 Presents a Preferred Reporting Items For Systematicmentioning

confidence: 99%

Section: Figure 1 Presents a Preferred Reporting Items For Systematicmentioning

confidence: 99%

Section: Figure 1 Presents a Preferred Reporting Items For Systematicmentioning

confidence: 99%

Section: Pharmaceutical Therapies In Neuropathic Painmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

A systematic review of cost-effectiveness modeling of pharmaceutical therapies in neuropathic pain: variation in practice, key challenges, and recommendations for the future

Critchlow

Hirst

Akehurst

et al. 2016

Journal of Medical Economics

View full text Add to dashboard Cite

show abstract

Cost-Effectiveness of Treatment Options for Neuropathic Pain: a Systematic Review

et al. 2019

View full text Add to dashboard Cite

Topical Analgesics in the Management of Acute and Chronic Pain

Argoff

2013

Mayo Clinic Proceedings

107

View full text Add to dashboard Cite

Oral analgesics are commonly prescribed for the treatment of acute and chronic pain, but these agents often produce adverse systemic effects, which sometimes are severe. Topical analgesics offer the potential to provide the same analgesic relief provided by oral analgesics but with minimal adverse systemic effects. This article describes the results of a systematic review of the efficacy of topical analgesics in the management of acute and chronic pain conditions. A literature search of MEDLINE/PubMed was conducted using the keywords topical analgesic AND chronic pain OR acute pain OR neuropathic pain and focused only on individual clinical trials published in English-language journals. The search identified 92 articles, of which 65 were eligible for inclusion in the review. The most commonly studied topical analgesics were nonsteroidal anti-inflammatory drugs (n=27), followed by lidocaine (n=9), capsaicin (n=6), amitriptyline (n=5), glyceryl trinitrate (n=3), opioids (n=2), menthol (n=2), pimecrolimus (n=2), and phenytoin (n=2). The most common indications were acute soft tissue injuries (n=18), followed by neuropathic pain (n=17), experimental pain (n=6), osteoarthritis and other chronic joint-related conditions (n=5), skin or leg ulcers (n=5), and chronic knee pain (n=2). Strong evidence was identified for the use of topical diclofenac and topical ibuprofen in the treatment of acute soft tissue injuries or chronic joint-related conditions, such as osteoarthritis. Evidence also supports the use of topical lidocaine in the treatment of postherpetic neuralgia and diabetic neuropathy. Currently, limited evidence is available to support the use of other topical analgesics in acute and chronic pain.

show abstract

Cost Effectiveness of a Lidocaine 5% Medicated Plaster Compared with Pregabalin for the Treatment of Postherpetic Neuralgia in the UK

Cited by 13 publications

References 47 publications

A systematic review of cost-effectiveness modeling of pharmaceutical therapies in neuropathic pain: variation in practice, key challenges, and recommendations for the future

A systematic review of cost-effectiveness modeling of pharmaceutical therapies in neuropathic pain: variation in practice, key challenges, and recommendations for the future

Cost-Effectiveness of Treatment Options for Neuropathic Pain: a Systematic Review

Topical Analgesics in the Management of Acute and Chronic Pain

Contact Info

Product

Resources

About